Drug Trial Radar · NCT02246595
Studying Complement Inhibition in Early, Newly Developing Septic Organ Dysfunction
Last checked: Nov 19, 2026Latest source record: Apr 25, 2016 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
72
Actual
Start
Apr 2014
Primary completion
Dec 2015
Study completion Dec 2015
Sponsor
- Lead sponsor
- InflaRx GmbHIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The trial enrolls patients with early severe sepsis or septic shock displaying at least one newly developed organ dysfunction and showing clinical evidence of pulmonary or abdominal infection. The primary goal of the trial is to assess the pharmacokinetics and pharmacodynamics of the new monoclonal antibody CaCP29 and to characterize safety and tolerability as well as evaluate parameters of efficacy.
Conditions
- Severe Sepsis
- Septic Shock
Interventions
CaCP29Biological
PlaceboBiological
Primary outcomes
What the sponsor says the trial is designed to measure.
- Plasma Concentration of CaCP29Time frame: 0h, 2h, 6h, 12h, 14h (only cohort 1), 24h, 26h (only cohort 2 and 3), 48h, 72h, 74h (only cohort 3), days 5, 8, 13, 28
- Assess the pharmacodynamic (PD) effects of CaCP29 on the change from baseline in plasma concentrations of C5aTime frame: 0h, 2h, 6h, 12h, 14h (only cohort 1), 24h, 26h (only cohort 2 and 3), 48h, 72h, 74h (only cohort 3), days 5, 8, 13, 28
- Safety variables will be summarized using descriptive statistics based on adverse event collectionTime frame: 28 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Study Site
Aachen, Germany
Study Site
Augsburg, Germany
Study Site
Bad Saarow, Germany
Study Site
Berlin, Germany
Study Site
Göttingen, Germany
Study Site
Greifswald, Germany
Study Site
Hamburg, Germany
Study Site
Jena, Germany
Study Site
Kiel, Germany
Study Site
Leipzig, Germany
Study Site
Oldenburg, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.